Arthur C. Santora II - 24 Apr 2023 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Reporting relationship: Chief Medical Officer
Issuer ticker: ENTX
Reported as of: 24 Apr 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Apr 2023, 17:21:08 UTC
Prior SEC filing: 09 Sep 2022
Source filing: View source filing
Reporting owner signature: /s/ Dana Yaacov-Garbeli, Attorney-in-Fact

Key filing fact

Arthur C. Santora II filed Form 4 for Entera Bio Ltd. (ENTX) on 25 Apr 2023.

Key facts

This page summarizes Arthur C. Santora II's Form 4 filing for Entera Bio Ltd. (ENTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 25 Apr 2023, 17:21.

Change

Previous filing in this sequence was filed on 09 Sep 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ENTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +35,000
Change %
Price: $0.000000
Shares after: 35,000
Date: 24 Apr 2023
Ownership: Direct
Underlying class: Ordinary Shares, par value NIS 0.0000769 per share
Underlying amount: 35,000
Exercise price: $0.7950
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options vest over a four-year period with 25% of the options vesting on April 24, 2024, the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.